Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Allison Upalawanna"'
Autor:
David Planchard, Julien Mazieres, James R. Rigas, Bruce E. Johnson, Allison Upalawanna, Benjamin Besse, Tae Min Kim, Pierre-Jean Souquet, Silvia Novello, Bijoyesh Mookerjee, Christina S. Baik, Anthony D'Amelio, Harry J.M. Groen, Elisabeth Quoix, Fabrice Barlesi, Pingkuan Zhang
Publikováno v:
Lancet Oncology, 17(7), 984-993. ELSEVIER SCIENCE INC
Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity in patients with BRAF(V600E)-mutant NSCLC. Dual MAPK pat
Autor:
Georgina V. Long, Mathilde Kaper, James Larkin, Eduard Gasal, Ana Maria Arance Fernandez, Johan Hansson, Victoria Atkinson, Allison Upalawanna, Reinhard Dummer, Bijoyesh Mookerjee
Publikováno v:
Journal of Clinical Oncology. 36:189-189
189 Background: Checkpoint inhibitors and targeted therapies have improved outcomes in pts with advanced BRAF V600–mutant melanoma; however, many still progress and die from this disease. Thus, new treatment strategies are needed. BRAF and MEK inhi
Autor:
Yongyu Wang, P.C. Fong, Rebecca Kristeleit, Neil Finkler, Rodney P. Rocconi, Allison Upalawanna, Agustin A. Garcia, Matt Squires, Gottfried E. Konecny, Paula S. Lee, Kaushal Mishra, Domenica Lorusso
Publikováno v:
The Lancet. Oncology, vol 16, iss 6
Konecny, GE; Finkler, N; Garcia, AA; Lorusso, D; Lee, PS; Rocconi, RP; et al.(2015). Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. The Lancet Oncology, 16(6), 686-694. doi: 10.1016/S1470-2045(15)70159-2. UCLA: Retrieved from: http://www.escholarship.org/uc/item/6v59m7fh
Konecny, GE; Finkler, N; Garcia, AA; Lorusso, D; Lee, PS; Rocconi, RP; et al.(2015). Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. The Lancet Oncology, 16(6), 686-694. doi: 10.1016/S1470-2045(15)70159-2. UCLA: Retrieved from: http://www.escholarship.org/uc/item/6v59m7fh
© 2015 Elsevier Ltd. Background: Activating FGFR2 mutations are found in 10-16% of primary endometrial cancers and provide an opportunity for targeted therapy. We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa68699850379f34bb7985a413e4292
https://escholarship.org/uc/item/6v59m7fh
https://escholarship.org/uc/item/6v59m7fh
Autor:
Daniel Shao-Weng Tan, Alfredo Berruti, Egbert F. Smit, Allison Upalawanna, Hans-Georg Kopp, Alexander I. Spira, Noemi Reguart, Matthew Squires, Igor I. Rybkin, Mikhail Akimov, Karl Maria Schumacher, Dong Wan Kim, Dae Ho Lee
Publikováno v:
Journal of Thoracic Oncology. 11:S307-S308
Autor:
James Larkin, Eduard Gasal, Antoni Ribas, Keith T. Flaherty, Dirk Schadendorf, C. Robert, Jessica C. Hassel, J.-J. Grob, Reinhard Dummer, Wilson H. Miller, Paul Nathan, V. Atkinson, Céleste Lebbé, Hussein Abdul-Hassan Tawbi, Paul Lorigan, Georgina V. Long, Allison Upalawanna, A.M. Arance Fernandez, Johan Hansson, P.A. Ascierto
Publikováno v:
Annals of Oncology. 28:v447
Autor:
Egbert F. Smit, Alexander I. Spira, Allison Upalawanna, Alfredo Berruti, Daniel Shao-Weng Tan, Matthew Squires, Giampaolo Tortora, Mikhail Akimov, Cindy Xu, Noemi Reguart, Dong Wan Kim, Karl Maria Schumacher, Dae Ho Lee, Hans-Georg Kopp, Igor I. Rybkin
Publikováno v:
Journal of Clinical Oncology. 34:TPS9109-TPS9109
TPS9109Background: Despite high overall response rates (ORR) to EGFR TKIs, most pts with EGFR-mutated NSCLC develop acquired resistance; secondary activation of cMET as gene amplification, occurs i...
Autor:
Anthony D'Amelio, James R. Rigas, Elisabeth Quoix, Pierre Jean Souquet, Bruce E. Johnson, Pingkuan Zhang, Fabrice Barlesi, Silvia Novello, Christina S. Baik, Benjamin Besse, Allison Upalawanna, Harry J.M. Groen, David Planchard, Julien Mazieres, Bijoyesh Mookerjee, Tae Min Kim
Publikováno v:
Journal of Clinical Oncology. 34:107-107
107Background: BRAF V600E mutations occur in 1% to 2% of lung adenocarcinomas and act as an oncogenic driver. The BRAF inhibitor D has demonstrated clinical activity (33% overall response rate [ORR], with a median progression-free survival [PFS] of 5
Autor:
P.C. Fong, Kaushal Mishra, N. Finkler, Paula S. Lee, Rebecca Kristeleit, Y.A. Wang, Matthew Squires, Allison Upalawanna, Gottfried E. Konecny, Domenica Lorusso, A. A. Garcia, Rodney P. Rocconi
Publikováno v:
Annals of Oncology. 25:v1
Aim: Activating mutations in FGFR2, identified in 10%-15% of primary endometrial cancers (ECs), are associated with disease progression and poor outcome. Here, we evaluate dovitinib, a potent tyrosine kinase inhibitor of FGFR, VEGFR, and PDGFR, as se
Autor:
Agustin A. Garcia, Gottfried E. Konecny, M Jesus Rubio, Rodney P. Rocconi, A. Yovine, Michael McCollum, Neil J. Finkler, Matthew Squires, Allison Upalawanna, Nicoletta Pirotta, Francesco Raspagliesi, Carolina Muriel Lopez
Publikováno v:
Journal of Clinical Oncology. 31:TPS5616-TPS5616
TPS5616 Background: Despite the use of combination chemotherapy and introduction of novel targeted agents, the prognosis for advanced and/or metastatic EC is challenging. The occurrence of somatic activating FGFR2 mutations in EC suggests an opportun